Cost of Revenue: Key Insights for Catalent, Inc. and Celldex Therapeutics, Inc.

Catalent vs. Celldex: A Decade of Revenue Cost Insights

__timestamp	Catalent, Inc.	Celldex Therapeutics, Inc.
Wednesday, January 1, 2014	1229100000	101881000
Thursday, January 1, 2015	1215500000	4011000
Friday, January 1, 2016	1260500000	102026000
Sunday, January 1, 2017	1420800000	96171000
Monday, January 1, 2018	1710800000	66449000
Tuesday, January 1, 2019	1712900000	42672000
Wednesday, January 1, 2020	2111000000	42534000
Friday, January 1, 2021	2646000000	3068000
Saturday, January 1, 2022	3188000000	1400000
Sunday, January 1, 2023	3216000000	3008000
Monday, January 1, 2024	3428000000

Cracking the code

Cost of Revenue: A Tale of Two Companies

In the ever-evolving landscape of the pharmaceutical industry, understanding the cost of revenue is crucial for assessing a company's financial health. Catalent, Inc. and Celldex Therapeutics, Inc. offer a fascinating contrast in this regard. Over the past decade, Catalent has seen a robust growth trajectory, with its cost of revenue increasing by approximately 179% from 2014 to 2023. This reflects its expanding operations and market reach. In stark contrast, Celldex Therapeutics has experienced a more volatile journey, with its cost of revenue peaking in 2016 and then declining significantly. By 2023, Celldex's cost of revenue had plummeted by over 97% from its 2016 high, indicating strategic shifts or operational challenges. This data underscores the dynamic nature of the industry and highlights the importance of strategic financial management.

Published by

U.S. Securities and Exchange Commission

Source link

sec.gov

Date published

17 Jan 2025